Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.41 |
| ▸ | CDK2 | P24941 | 5/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.41 |
| ▸ | CDK1 | P06493 | 3/20 | 0.40 |
| ▸ | CDK4 | P11802 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | CCND1 | P24385 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29224924 | 0.86 | MAPT (0.46) | HDAC1MAPTCDK2POLBMAPK1 | |
| SCHEMBL27947891 | 0.83 | MAPT (0.56) | HDAC1MAPTCDK2POLBMAPK1 | |
| SCHEMBL13528619 | 0.82 | CYP1A2 (0.52) | MAPTLMNAGAAMEN1ALDH1A1 | |
| SCHEMBL26830431 | 0.78 | MAPK1 (0.62) | HDAC1MAPK7KAT2BCCNA2CDK2 | |
| SCHEMBL2950329 | 0.76 | HDAC1 (0.47) | HDAC1MAPK7KAT2BCCNA2CDK2 | |
| SCHEMBL6125260 | 0.76 | POLB (0.69) | PKMMAPTPOLBMAPK1LMNA | |
| SCHEMBL29225001 | 0.75 | ALDH1A1 (0.41) | MAPTPOLBMAPK1LMNAGAA | |
| SCHEMBL25086292 | 0.75 | PRKCQ (0.50) | MAPTPOLBLMNAGAAMEN1 | |
| SCHEMBL17832701 | 0.75 | HDAC1 (0.55) | HDAC1MAPK7KAT2BCCNA2CDK2 | |
| SCHEMBL13162840 | 0.74 | KDM4E (0.60) | CCNA2CDK2CCNA1CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928844-B1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8492404-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1928844-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007022380-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | LCK, BTK, IRAK1 | HDAC1 916/4885MAPK7 242/4885PKM 358/4885 |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | LCK, BTK, IRAK1 | HDAC1 916/4885MAPK7 242/4885PKM 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.